68Ga-PSMA PET in the Renal Cell Carcinoma

Key facts

Sponsor

Xijing Hospital

Intervention

PSMA PET(diagnostic_test)

Enrollment

300 target

Eligibility

18-90 years · All sexes

Timeline

2021 – 2027

Study locations (9)

• The First Hospital of Lanzhou University, Lanzhou, Gansu, China
• General Hospital of Ningxia Medical University, Yinchuan, Ningxia, China
• Qinghai University Affiliated Hospital, Xining, Qinghai, China
• Xijing Hospital, Xi'an, Shaan'xi, China
• Weinan Central Hospital, Weinan, Shaanxi, China
• Shaanxi Provincial People's Hospital, Xi'an, Shaanxi, China
• Xijing 986 Hospital, Xi'an, Shaanxi, China
• The Second Affiliated Hospital of Shaanxi University of Chinese Medicine, Xianyang, Shaanxi, China
• Affiliated Hospital of Yan'an University, Yan’an, Shaanxi, China

Collaborators

Air Force Military Medical University, China · Shaanxi Provincial People's Hospital · Yan'an University Affiliated Hospital · Weinan Central Hospital · The Second Affiliated Hospital of Shaanxi University of Chinese Medicine · LanZhou University · Affiliated Hospital of Qinghai University · General Hospital of Ningxia Medical University

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Acquired cystic disease-associated renal cell carcinoma

Additional recruiting or active studies for the same condition.

• RECRUITINGNANCT06882486
  Post-immunotherapy Nephrectomy for Metastatic Kidney Cancer After Complete or Major Response to Systemic Therapy
  Institut Paoli-Calmettes
• RECRUITINGPHASE1NCT07517198
  Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors
  Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
• RECRUITINGNANCT06907095
  Cohort Evaluation of Body Fluids Early Detection of Cancer in High-risk Individuals
  Gustave Roussy, Cancer Campus, Grand Paris
• RECRUITINGNANCT07461090
  Laparoscopic Versus Open Nephrectomy : Clinical Effectivness and Cost Analysis
  Menoufia University
• RECRUITINGPHASE1NCT07195682
  A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
  Bristol-Myers Squibb
• RECRUITINGPHASE1NCT07006688
  A Study of an IDH1m Inhibitor in Participants With IDH1-Mutated Malignancies and Hepatic or Renal Impairment
  Servier Bio-Innovation LLC
• RECRUITINGPHASE1, PHASE2NCT07219576
  Retifanlimab and Ruxolitinib In Solid Malignancies
  University of California, San Diego
• RECRUITINGPHASE1, PHASE2NCT07239596
  Phase Ib/II Clinical Study of SHR-8068 Combined With Adebrelimab and Other Anti-tumor Drugs in the Treatment of Advanced Renal Cell Carcinom
  Suzhou Suncadia Biopharmaceuticals Co., Ltd.

See all trials for Acquired cystic disease-associated renal cell carcinoma →